Understanding Age-Related Macular Degeneration and Its Progression

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational project aims to comprehensively characterize age-related macular degeneration (AMD) by investigating its underlying causes, the differences in AMD phenotypes, and the factors influencing disease progression. Participants will include individuals with AMD as well as healthy controls, and data will be collected through non-invasive imaging, biological samples, and patient-reported outcomes. The study seeks to enhance our understanding of AMD's natural history and the rate at which it progresses.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. 18 years of age or older; and
2. either AMD (defined as having at least a medium druse \>63 um), or having eyes with normal ageing changes (including small drusen ≤63 um) or no abnormalities as control participants

Exclusion Criteria:

1. ocular or systemic conditions other than AMD that could compromise retinal assessment or assessment of AMD and its progression; or
2. any participant with any mental or physical impairment that prevents them from signing an informed consent form or participating in this study.

Where it's running

• Centre for Eye Research Australia
  East Melbourne, Victoria, Australia Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• C.001 for retinal degeneration: a first-in-human dose-escalation safety test

  A first-in-human study will test the safety and tolerability of a single subretinal injection of C.001 in adults with retinal diseases involving retinal pigment epithelium degeneration.

  Recruiting at 2 sites Phase 1 Cellio Therapeutics Inc · Beverly Hills, California and 2 other locations · NCT07594236

• Central microperimetry and radial OCT in geographic atrophy

  We will test whether central microperimetry and radial OCT scans can more accurately measure how geographic atrophy progresses toward the fovea in people with or at risk for GA from age-related macular degeneration.

  Recruiting University of California, San Francisco · San Francisco, California · NCT07556406

• Eye injections of ABBV-6628 for geographic atrophy from age-related macular degeneration

  This trial will test whether intravitreal ABBV-6628 is safe and how the drug moves through the body in adults aged 50 and older with geographic atrophy from AMD.

  Recruiting at 5 sites Phase 1/2 AbbVie · Carmel, Indiana and 4 other locations · NCT07160179

• Evaluating a stem cell treatment for geographic atrophy from dry age-related macular degeneration.

  This study is testing a new stem cell treatment for people with geographic atrophy from dry age-related macular degeneration to see if it can help improve their vision.

  Recruiting at 3 sites Phase 1/2 Eyestem Research Pvt. Ltd. · Jālna, Maharashtra and 2 other locations · NCT06394232

• Monitoring progression of non-foveal age-related macular degeneration using artificial intelligence

  This study is testing how well artificial intelligence can help track the progression of a specific type of age-related macular degeneration in patients over two years.

  Recruiting at 6 sites Medical University of Vienna · Vienna and 6 other locations · NCT06351657

• New telescope implant for patients with late-stage age-related macular degeneration

  This study is testing a new small telescope implant to see if it can help older patients with severe vision loss from age-related macular degeneration see better after surgery.

  Recruiting at 10 sites VisionCare, Inc. · Loma Linda, California and 9 other locations · NCT05438732

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.